Bruker closes acquisition of Michrom

NewsGuard 100/100 Score

Bruker today announced the closing of its acquisition of Michrom Bioresources, Inc. (Michrom), a 20 year old, privately owned company located in Auburn, California, after receiving unanimous Michrom shareholder approval. The acquisition is not expected to have a material effect on Bruker's 2011 financials.

All former Michrom employees have been offered employment by Bruker, and Michrom's founder, Mr. Kerry Nugent, has joined Bruker as 'Senior Vice President - Liquid Chromatography'. Michrom has been renamed 'Bruker-Michrom Inc.', and will operate out of R&D and manufacturing operations in Auburn, CA and Fremont, CA, as part of the Bruker Chemical & Applied Markets (CAM) division.

Bruker intends to invest in the further development of the proprietary CaptiveSpray™ Ionization (CSI) sources for LC-MS, of HPLC liquid chromatography systems, and of related novel LC accessory, software and consumables products.

In related news, the Bruker CAM division has now moved its GC-MS operations and headquarters out of the previous Varian Walnut Creek, CA facility, and into a major new Bruker Fremont facility. Activities at this expanded facility include GC-MS and LC-MS R&D and manufacturing, as well as applications development, customer demonstrations, service and training for many other Bruker scientific instruments product lines, including NMR, FTIR/Raman, life-science mass spectrometry, GC and LC separations, elemental analysis and X-ray diffraction.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Balancing efficacy and safety: The challenges of mRNA drugs and vaccines in modern medicine